Sarepta Could More Than Double Its Addressable Market In A Few Years, But Eteplirsen Isn't The 'Be All End All'
September 29, 2016 at 09:28 AM EDT
Sarepta Therapeutics Inc (NASDAQ: SRPT) announced the commencement of dosing in the Phase III ESSENCE study of SRP-4045 and ...